Sign In
Buy INVVY
$21.85
+0 (+0%)
At Close: Sep 08, 2023
Indivior PLC (INDV) Tops Q2 Earnings and Revenue Estimates
09:16am, Thursday, 31'st Jul 2025
Indivior PLC (INDV) came out with quarterly earnings of $0.51 per share, beating the Zacks Consensus Estimate of $0.26 per share. This compares to earnings of $0.44 per share a year ago.
Indivior Reports Second Quarter 2025 Financial Results and Raises FY 2025 Financial Guidance
07:00am, Thursday, 31'st Jul 2025
Q2'25 Total Net Revenue of $302m; Q2'25 SUBLOCADE® Net Revenue of $209m, up 9% Year-over-Year Indivior Action Agenda Underway to Strengthen Business and Generate Operational Momentum Conference Call
SLOUGH, United Kingdom and RICHMOND, Va. , July 25, 2025 /PRNewswire/ -- Further to the announcement made on June 2, 2025, Indivior PLC (Nasdaq: INDV) today announces that: (i) the secondary listing o
Extended-release buprenorphine (BUP-XR) had lower rates of hospitalizations, emergency department (ED) visits, and outpatient physician office visits compared to those receiving daily oral bupreno
Indivior to Report Second Quarter 2025 Financial Results and Host Webcast on July 31st
09:00am, Thursday, 17'th Jul 2025
RICHMOND, Va. , July 17, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq / LSE: INDV) today announced that it will report second quarter 2025 financial results on Thursday, July 31, 2025 at 7:00 a.m.
Indivior (INDV) Moves 5.7% Higher: Will This Strength Last?
08:05am, Tuesday, 01'st Jul 2025
Indivior (INDV) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in
Indivior Announces Inclusion in the U.S. Russell 2000® and 3000® Indexes
07:00am, Monday, 30'th Jun 2025
RICHMOND, Va., June 30, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq / LSE: INDV) will be added as a member of the U.S. small-cap Russell 2000® Index, effective after the U.S. market opens today as pa
Indivior Presents New Data at CPDD Demonstrating that High Buprenorphine Exposure May Improve Treatment Outcomes in High Fentanyl Users
09:00am, Thursday, 19'th Jun 2025
A post-hoc analysis demonstrates that buprenorphine exposure with 300 mg SUBLOCADE® (buprenorphine extended-release) may improve treatment outcomes among opioid use disorder (OUD) patients with heavy
Indivior to delist from London Stock Exchange, maintain Nasdaq listing
02:33am, Monday, 02'nd Jun 2025
Pharma firm Indivior said on Monday it will cancel its secondary listing on the London Stock Exchange, effective July 25, maintaining its primary listing on the Nasdaq to reduce costs and better align
Addex Partner Indivior Advances GABAB Positive Allosteric Modulator Program Successfully Through IND Enabling Studies
01:00am, Monday, 12'th May 2025
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, May 12, 2025 - Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of no
Indivior PLC (INDV) Q1 2025 Earnings Conference Call Transcript
10:45am, Thursday, 24'th Apr 2025
Indivior PLC (NASDAQ:INDV ) Q1 2025 Earnings Conference Call April 24, 2025 8:00 AM ET Company Participants Jason Thompson - Head, IR Mark Crossley - CEO Ryan Preblick - CFO Conference Call Participan
Indivior PLC (INDV) Q1 Earnings and Revenues Beat Estimates
08:05am, Thursday, 24'th Apr 2025
Indivior PLC (INDV) came out with quarterly earnings of $0.41 per share, beating the Zacks Consensus Estimate of $0.22 per share. This compares to earnings of $0.37 per share a year ago.
Indivior Announces Further Changes to Board of Directors
08:40am, Tuesday, 04'th Mar 2025
RICHMOND, Va. , March 4, 2025 /PRNewswire/ -- Indivior PLC (NASDAQ / LSE: INDV) ("Indivior" or the "Company") today announced that, further to the announcement on December 17, 2024 of certain Directo
UK's Indivior appoints Joe Ciaffoni as CEO
02:48am, Thursday, 27'th Feb 2025
British drugmaker Indivior on Thursday said it appointed Joe Ciaffoni as its new CEO, replacing current boss Mark Crossley.
Indivior Announces Joseph Ciaffoni Appointed Chief Executive Officer
02:00am, Thursday, 27'th Feb 2025
RICHMOND, Va. , Feb. 27, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq/LSE: INDV) has appointed Joe Ciaffoni, currently an Independent Non-Executive Director of the Company, as Chief Executive Officer.
